CJC-1295 with DACvsTesamorelin

CJC-1295 with DAC shares the same core peptide sequence and GHRH receptor binding mechanism as the no-DAC version — it activates Gs/adenylyl cyclase/cAMP/PKA signaling in pituitary somatotrophs to stimulate GH synthesis and secretion. The critical difference is the Drug Affinity Complex (DAC), a reactive N-hydroxysuccinimide ester linker attached to the peptide that covalently and irreversibly binds to circulating serum albumin after injection.

Albumin is the most abundant plasma protein with a half-life of approximately 19 days. By permanently conjugating to albumin, the DAC moiety transforms CJC-1295 from a short-acting peptide (30-minute half-life) into a long-circulating molecule with a half-life of 6-8 days. The albumin-bound peptide continuously activates GHRH receptors as it circulates, producing a sustained elevation of GH levels rather than discrete pulses.

This sustained GH elevation is both the advantage and disadvantage of the DAC version. The convenience of weekly dosing is appealing, and total GH output over time may be higher. However, continuous GHRH receptor stimulation can lead to receptor desensitization (tachyphylaxis), and the loss of natural pulsatility may reduce the efficiency of GH signaling at target tissues. Somatostatin — the hypothalamic hormone that normally creates the troughs between GH pulses — is partially overridden by continuous receptor stimulation, which blunts the natural feedback regulation. Some practitioners also express concern that sustained GH elevation more closely mimics the pathological hormone profile of acromegaly than the healthy pulsatile pattern.

Tesamorelin is a synthetic GHRH analogue consisting of all 44 amino acids of human GHRH with a trans-3-hexenoic acid group attached to the tyrosine at position 1. This lipophilic modification enhances receptor binding affinity and provides modest resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage, improving its pharmacokinetic profile compared to native GHRH.

Like other GHRH analogues, tesamorelin activates the GHRH receptor on pituitary somatotrophs via the Gs/cAMP/PKA pathway, stimulating endogenous GH synthesis and pulsatile secretion. The resulting increase in circulating GH and IGF-1 produces its primary therapeutic effect: targeted reduction of visceral adipose tissue (VAT). GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation.

The specificity of tesamorelin's effect on visceral rather than subcutaneous fat has been well-documented in clinical trials. Visceral adipose tissue is metabolically distinct — it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone. Clinical trials also showed improvements in hepatic steatosis (fatty liver) markers, triglyceride levels, and trunk fat distribution. It remains the only GHRH analogue with active FDA approval, specifically for HIV-associated lipodystrophy, where visceral fat accumulation is a common and distressing side effect of antiretroviral therapy.